Merck
Contact information
- A. Health Biotechnology
- Areas of activity
- Vaccines
- Therapeutic areas
- Musculoskeletal system
- Cardiovascular diseases and circulatory system
- Genetic and rare diseases
- Inflammatory diseases
- Gynaecology and obstetrics
- Immunology
- Oncology
- Central nervous system
- Metabolic disorders / Endocrinology
- C. Industrial Biotechnology
- APIs and green chemistry
- Purification resins
- D. Services
- Professional services
- Investment / Venture Capital
Merck is the pharmaceutical and chemical company with more tradition in the world, with origins in 1668. Merck seeks business success with a formula based on values and generate economic value. Our strategy is supported on three concepts that define Merck's strategy: Sustain, Change and Grow.
Merck is concentrated in two business segments: pharmaceuticals and chemicals. All activity of the company is organized into four Divisions: Merck Serono and Merck Consumer Health Care (pharmaceutical) and Performance Materials and Merck Millipore (chemical).
The Merck Serono division aims to provide innovative solutions to patients. We are specialized in the treatment of cancer, neurological diseases, infertility, hormonal and metabolic disorders, cardiovascular disease and other diseases with significant unmet medical needs, such as phenylketonuria. And we continue investigating to provide patients with therapeutic advances in our actual business.
Biotech Sanitaria
| Product / Service | Type | Therapeutic area | Development phase |
|---|---|---|---|
| Xevinapant (IAP inhibitor) | Biodrugs/ Drugs | Oncología | P III |
| Xevinapant (IAP inhibitor) | Biodrugs/ Drugs | Oncología | P III |
| Tepotinib (MET kinase inhibitor) | Biodrugs/ Drugs | Oncología | P II |
| M9140 (anti-CEACAM5 Ab drug conjugate) | Biodrugs/ Drugs | Oncología | P I |
| M1774 (ATR inhibitor) | Biodrugs/ Drugs | Oncología | P I |
| M1774 (ATR inhibitor) | Biodrugs/ Drugs | Oncología | P I |
| Evobrutinib (BTK inhibitor) | Biodrugs/ Drugs | Sistema nervioso central | P III |
| Enpatoran (TLR7/8 antagonist) | Biodrugs/ Drugs | P II | |
| Avelumab (anti-PD-L1 inhibitor) | Biodrugs/ Drugs | Oncología | Registration |
| Product / Service | Type | Therapeutic area | Development phase |
|---|---|---|---|
| Liquid Biopsy RAS Biomarker Testing | Biomarkers, Diagnostic | Oncología, Sistema digestivo y hepatología | R&D |